Why is Genscript Biotech stock surging today?

Genscript Biotech stock experienced a remarkable 16.2% surge to HK$37.82 on Thursday, buoyed by investor enthusiasm following the company's partnership with Eli Lilly's Tunelab™ platform. Tunelab is an innovative AI and machine learning-driven drug discovery initiative that will see GenScript providing wet lab services to translate computational predictions into tangible biological validation data, thereby accelerating the evaluation of potential drug candidates.

The momentum behind Genscript's stock rise was further fueled by the company's completion of a substantial share placement, which raised approximately HK$2.35 billion in net proceeds. Roughly 70% of this capital is earmarked for expanding the AI drug discovery platform's capacity and infrastructure, while an additional 20% is designated for related research and development activities and digital workflow integration.

This positive development was not isolated to Genscript alone, as other players within the Hong Kong Contract Research Organization (CRO) sector also experienced gains, contributing to a broader re-rating of AI drug discovery-linked names on the exchange. However, the broader Hong Kong stock market experienced a downturn, with the Hang Seng index falling by 0.9%.